Table 3.
Eligibility criteria for overall survival benefit with ramucirumab, cabozantinib, and regorafenib as the second line of treatment for HCC.
| Main | |
| Male patients | |
| ECOG: 0 | |
| Extrahepatic metastases | |
| HBV infection | |
|
| |
| Independent | |
| Age | |
| Alpha-fetoprotein | |
| Macrovascular invasion | |